Meta-analysis of the risk of torsades de pointes in patients treated with intravenous racemic sotalol

Academic Emergency Medicine

Volumn 8, Issue 2, 2001, Pages 117-124

  Marill, Keith A ^a   Runge, Tim ^b  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adverse effects; Infusions, intravenous; Sotalol; Tachycardia, supraventricular; Tachycardia, ventricular; Torsades de pointes

Indexed keywords

SOTALOL;

ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; QT INTERVAL; RISK ASSESSMENT; TORSADE DES POINTES; WOLFF PARKINSON WHITE SYNDROME;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RISK FACTORS; SOTALOL; TORSADES DE POINTES;

EID: 0035144158     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2001.tb01275.x     Document Type: Article

References (69)

1. Sotalol: An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias
2. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia
3. Termination of refractory ventricular tachycardia by a combination of intravenous sotalol and overdrive ventricular pacing
4. Beta-blockade by sotalol in early myocardial infarction decreases ventricular arrhythmias without increasing left ventricular volume
5. Effect of sotalol on ventricular fibrillation and defibrillation in humans
6. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia
7. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
8. Elektophysiologische wirkung von sotalol bei supraventrikularen tachykardien
9. Mechanisms of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol
10. Adenosine for paroxysmal supraventricular tachycardia: Dose ranging and comparison with verapamil
11. Sotalol in patients with Wolff-Parkinson-White syndrome
12. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome
13. Effects of intravenous sotalol in patients with atrioventricular accessory pathways
14. Electrophysiological effects of sotalol - Just another beta blocker?
15. Atrial fibrillation in Wolff-Parkinson-White syndrome: Reversal of isoproterenol effects by sotalol
16. Acute prolongation of myocardial refractoriness by sotalol
17. Clinical safety profile of sotalol in the treatment of arrhythmias
18. Clinical safety profile of sotalol in patients with arrhythmias
19. Sex difference in risk of torsades de pointes with d, l-sotalol
20. T wave alternans after sotalol: Evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm
21. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: Reversal by magnesium
22. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone
23. Reproducible induction of early afterdepolarizations and torsades de pointes arrhythmias by D-sotalol and pacing in dogs with chronic atrioventricular block
24. Using meta-analysis for research synthesis: Pooling data from several studies
25. Plasmaspiegel und wirkung von sotalol-HCl auf EKG-Zeitintervalle nach parenteraler applikation an gesunde probanden
26. Acute and chronic effects of sotalol and propanolol on ventricular repolarization using constant-rate pacing
27. The relationship between heart rate and QT interval during atrial stimulation
28. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle
29. Efficacy of sotalol in controlling reentrant supraventricular tachycardias
30. Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia
31. Sotalol-induced delayed ventricular repolarization in man
32. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation
33. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold
34. Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion
35. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrilllation
36. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter
37. Effects of procainamide and DL-sotalol on the changes of atrial electrophysiology induced by high current stimulation
38. Tachycardia-induced change of atrial refractory period in humans: Rate dependency and effects of antiarrhythmic drugs
39. Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing
40. Effects of intravenous sotalol, aprindine and the combination of sotalol and aprindine on chronic high frequency ventricular arrhythmias in man
41. Rapid intravenous infusion of D-L sotalol: Time to onset of effects on ventricular refractoriness, and safety
42. Does sotalol have reverse-use dependence during tachyarrhythmias?
43. Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease
44. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia
45. Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol
46. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias
47. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease
48. Multicenter trial sotalol compared with procainamide in the suppresion of inducible ventricular tachycardia: A double-blind, randomized parallel evaluation
49. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia
50. Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: Assessment of the electrophysiological effects by biatrial basket electrodes
51. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation
52. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol
53. Beta blockade during and after myocardial infarction: An overview of the randomized trials
54. A comparison of statistical methods for combining event rates from clinical trials
55. Meta-analysis; formulating, evaluating, combining, and reporting
56. Plasma catecholamine levels and cardiac rhythm before and after cardiac catheterisation
57. Randomized double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia and fibrillation
58. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias
59. Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease
60. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
61. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pre-treatment
62. Bretylium tosylate as initial treatment for cardiopulmonary arrest: Randomized comparison with placebo
63. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system
64. Efficacy of bretylium tosylate for ventricular tachycardia
65. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia
66. Current understanding of lidocaine as an antiarrhythmic agent: A review
67. Analysis of the treatment of spontaneous sustained stable ventricular tachycardia
68. The advantage of d-sotalol over dl-sotalol in a patient with ventricular arrhythmias and comorbid bronchospasm
69. Electrophysiologic effects of d-sotalol in humans